GoodRx Holdings SG&A Expenses 2019-2025 | GDRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

GoodRx Holdings sg&a expenses from 2019 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

GoodRx Holdings sg&a expenses from 2019 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Danaher (DHR)	$141.7B
CVS Health (CVS)	$78.2B
Elevance Health (ELV)	$66.8B
Cencora (COR)	$56.9B
DiDi Global (DIDIY)	$28B
Labcorp Holdings (LH)	$21B
Natera (NTRA)	$18.8B
BioMerieux (BMXMF)	$16B
EUROFINS SCIENT (ERFSF)	$14.7B
ICON (ICLR)	$13.6B
CochLear (CHEOY)	$13.5B
Solventum (SOLV)	$12.9B
Medpace Holdings (MEDP)	$12.3B
Revvity (RVTY)	$11.7B
Viatris (VTRS)	$11B
Avantor (AVTR)	$9.3B
Sonic Healthcare (SKHHY)	$9.1B
HealthEquity (HQY)	$8.4B
Charles River Laboratories (CRL)	$8.2B
Caris Life Sciences,�Inc (CAI)	$7.6B
Amplifon S.p.A (AMFPF)	$5.4B
Bausch + Lomb (BLCO)	$5B
BrightSpring Health Services (BTSG)	$3.7B
Sotera Health (SHC)	$3.4B
Surgery Partners (SGRY)	$2.8B
Organon (OGN)	$2.6B
Concentras Parent (CON)	$2.6B
Alignment Healthcare (ALHC)	$2.5B
GeneDx Holdings (WGS)	$2.4B
Progyny (PGNY)	$2B